The ROE as of December 2024 (TTM) for Immunome, Inc. (IMNM) is -139.72%

According to Immunome, Inc.’s latest financial reports and current stock price. The company's current ROE is -139.72%. This represents a change of 252.01% compared to the average of -39.69% of the last 4 quarters.

Immunome, Inc. (IMNM) Historical ROE (quarterly & annually)

How has IMNM ROE performed in the past?

The mean historical ROE of Immunome, Inc. over the last ten years is -57.63%. The current -139.72% ROE has changed 142.41% with respect to the historical average. Over the past ten years (40 quarters), IMNM's ROE was at its highest in in the September 2020 quarter at 17.07%. The ROE was at its lowest in in the March 2019 quarter at -103.66%.

Immunome, Inc. (IMNM) ROE by Quarter and Year

Discovering the peaks and valleys of Immunome, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Immunome, Inc. (IMNM) Average ROE

How has IMNM ROE performed in the past?

The current ROE of Immunome, Inc. (IMNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Immunome, Inc. (IMNM) ROE vs. Peers

How is IMNM’s ROE compared to its peers?

Immunome, Inc.’s ROE is greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Adagene Inc. (-50.10%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than AnaptysBio, Inc. (-287.94%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Molecular Partners AG (-39.16%), greater than MediciNova, Inc. (-20.70%), less than Champions Oncology, Inc. (66.22%), greater than Cyteir Therapeutics, Inc. (-9.44%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Rezolute, Inc. (-69.83%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than Gain Therapeutics, Inc. (-203.91%), greater than TFF Pharmaceuticals, Inc. (-310.17%), greater than aTyr Pharma, Inc. (-56.83%), greater than IN8bio, Inc. (-197.15%), greater than Lantern Pharma Inc. (-56.90%), greater than Ikena Oncology, Inc. (-39.59%), greater than Celcuity Inc. (-62.66%),

Build a custom stock screener for Immunome, Inc. (IMNM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunome, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immunome, Inc. (IMNM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immunome, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.